Table 3.

Percentage of men in all trials for whom an outcome is reported

Outcome	Slidenafil n = 7077	Tadalafil n = 2036	Vardenafil n = 3274
Efficacy
Improved erections	83	83	100
Mean # erections/week	20	0	0
Successful attempts at SI	47	72	100
More than 60/75% successful	10	0	18
More than 40% successful	0	0	0
Final score IIEF Q3	94	27	26
Mean change IIEF Q3	91	27	26
Final score IIEF Q4	94	27	26
Mean change IIEF Q4	91	27	26
Final score EF Domain	56	72	100
Mean change EF Domain	54	83	77
Normal EF at endpoint	8	56	14
Withdrawals
All-cause	83	65	69
Lack of efficacy	81	72	82
Adverse event	90	83	100
Adverse events
Men with any adverse event	42	40	18
Severe	27	25	35
Serious	38	83	78
Treatment related	55	3	43
Headache	99	90	86
Dyspepsia	79	71	73
Flushing	99	73	73
Nasal congestion/rhinitis	64	35	73
Visual disturbances	89	46	55
Back pain	13	73	9
Myalgia/increased CPK	16	60	18
Flu syndrome	17	30	34
CV events	24	27	33
Limb pain	10	11	0
Fatigue	3	15	0
Priapism	29	0	0
Nausea	14	0	0